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THE EFFECT OF A PUTATIVE ACYL-COA SYNTHETASE 5 INHIBITOR ON 
LIPID ACCUMULATION AND INSULIN RELEASE FROM CLONAL 
PANCREATIC −CELL 
YUHAN QIU  
ABSTRACT 
It is estimated by the World Health Organization (WHO) that 422 million people 
had diabetes worldwide in 2014, including 30.3 million people in the US. The cost of 
treating the disease is has tripled from 2003-2013 due to the increased number of patients. 
One of the genes strongly associated with type 2 diabetes (T2D) is the transcription factor 
7 like 2 (TCF7L2). A single nucleotide polymorphism (SNP) of the TCF7L2 results in 
increased expression of long chain acyl-CoA synthetase 5 (ACSL5) while deletion of this 
part of the TCF7L2 gene reduces ACSL5 mRNA level. The regulation of ACSL5 gene 
expression by the high risk TCF7L2 allele highlights the importance of investigating the 
role of ACSL5 in T2D. ACSL5 is one of a family of enzymes that activates FA to its CoA 
ester and is required for FA metabolism within cells. Mice lacking this protein have 
reduced fat mass and are more insulin sensitive.  
Chronic exposure of clonal pancreatic ß-cells to excess nutrients has been shown 
to result in increased intrinsic lipid droplets, reduced insulin content, a left-shift in glucose 
dose-dependent insulin secretion curve characterized by basal insulin hypersecretion (IH) 
and blunted glucose stimulated insulin secretion (GSIS). We tested the hypothesis that the 
use of a putative ACSL5 inhibitor (Adipo C) can reduce accumulated lipid droplets, rescue 
insulin content and reverse the left-shift in glucose dose-dependent insulin secretion curve.  
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INS-1 (823/13) cells were cultured in either 4 mM or 11 mM glucose media 
representing physiological and excess nutrients environment. Adipo C (10-25 µM) was 
added to cells to both acutely (2 hrs) and chronically (72 hrs) inhibit ACSL5 activity. Thin 
layer chromatography with C11 Bodipy fatty acid (BFA) was used to detect acute fatty 
acid incorporation into neutral lipids. Nile red was used to visualize intrinsic lipid droplets 
inside cells. Intracellular Ca2+ activity was detected using fura 2. Insulin assay was 
measured by HTRF. 
Acute fatty acid incorporation and lipid accumulation were reduced in cells exposed 
to Adipo C. An Adipo C concentration dependent right shift of glucose dose-dependent 
insulin release and increased insulin content were observed. 11 mM glucose cells cultured 
in 25 µM Adipo C showed decreased intracellular Ca2+ activity at 3 mM glucose and 
increased Ca2+ activity at 12 mM glucose, which are characteristic of cells cultured in 4 
mM glucose having reduced lipid stores. These results all indicate possible protective 
effects on -cells exposed to excess nutrients. Islets of T2D patients who have a 
physiologically elevated blood glucose level are exposed to a similar excess nutrient 
environment. Therefore, the results illustrated here warrant further research on Adipo C 
compound to explore its therapeutic potential on T2D.   
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Introduction 
Diabetes and its economic impact 
Diabetes is a chronic disease that occurs when the pancreas is incapable of 
producing enough insulin to regulate blood glucose level or when the body fails to respond 
to insulin (1). Type 1 diabetes, also known as insulin-dependent or childhood-onset 
diabetes, is characterized by deficiency in insulin production and it accounts for less than 
10% of total diabetes. The cause of type 1 is thought to be destruction of -cells due to 
autoimmune disease (2). Type 2 diabetes, formerly referred to as non-insulin-dependent 
diabetes, accounts for the vast majority of diabetes (1). It is estimated that 30.3 million 
people, 9.4% of the U.S. population, had diabetes in 2015, including type 1 and 2 (3). 
World Health Organization (WHO) report estimated that around 422 million adults, 300 
million more compared to 1980, had diabetes worldwide in 2014. Prevalence of diabetes 
globally has doubled in the past 3 decades, increasing from 4.7% to 8.5% (2). The 
substantial increase of the global prevalence in diabetes mirrored the similar trend in the 
rate of people who are obese or overweight (2). 
Diabetes imposes large economic burden on society via medical costs and indirect 
costs related to lose of productivity, increased mortality and so on. Direct medical costs 
involve the expenditure of outpatient and inpatient care for treating and preventing 
diabetes, medication and medical devices, and long-term care. It is estimated, by the 
International Diabetes Federation (IDF), that the total health-care expenditure on diabetes 
globally has tripled from 2003-2013 due to the increased number of diabetic patients and 
  
2 
per capita spending on diabetes (4). Also, the prevalence of diabetes has risen faster in 
developing countries than in developed countries (2). 
 
Classification of diabetes 
Diabetes mellitus is defined as a metabolic disorder of multiple etiology 
characterized by chronic hyperglycemia with disturbance of carbohydrate, fat and protein 
metabolism caused by defects in insulin secretion, insulin action, or both (1).  
Type 1 refers to the processes of -cell destruction that results in an “insulin 
required for survival” diabetes mellitus. Type 1 is usually characterized by the presence of 
anti-islet cell or insulin antibodies which are the indicators of autoimmune processes that 
lead to beta-cell destruction (5). 
Type 2 is characterized by disorders of insulin secretion and insulin action, both of 
which usually present at the same time. People with type 2 diabetes are frequently insulin 
resistant, which means resistant to the action of insulin. This form of diabetes can go on 
undiagnosed for years because hyperglycemia can often go unnoticed and does not provoke 
symptoms in early stages. There are other specific types of diabetes caused by less common 
causes (5). 
It is no longer recommended to use the term “insulin-dependent diabetes mellitus” 
and “non-insulin-dependent diabetes mellitus” because it classifies patients on the basis of 
treatment instead of pathogenic reasons (5). In clinical staging, diabetes mellitus can be 
subdivided into: Insulin requiring for survival, Insulin requiring for metabolic control, Not 
insulin requiring. (5)  
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Diagnosis criteria and complications of diabetes 
The diagnostic point for diabetes is fasting plasma glucose ≥ 7.0 mmol/L, selected 
based on micro-vascular complication.  However, the risk for macro-vascular disease, such 
as heart attack or stroke, increases even before the set diagnostic point. Impaired glucose 
tolerance (IGT) and Impaired fasting glycemia (IFG) are referred to as intermediate states 
between normal glucose homeostasis and diabetes. What should be noted is that IGT refers 
to abnormalities of glucose regulation in post prandial condition whereas IFG refers to 
impaired glucose regulation in the fasting state (5). 
Diabetes mellitus may present symptoms such as thirst, polyuria, blurring vision 
and weight loss. Consequences of these pathogenic processes include the wear-out of the 
-cells of the pancreas, insulin deficiency and insulin resistance. Uncontrolled diabetes can 
lead to severe eyesight impairment or blindness, kidney failure, and lower limb amputation. 
These long-term consequences significantly lower the life quality of diabetes patients. 
Diabetic retinopathy is responsible for 2.6% of blindness worldwide in 2010 (6). Data from 
54 countries demonstrates that 80% of end-stage renal disease (ESRD) results from 
diabetes, hypertension or a combination of the two (7). Individuals with diabetes 
historically have a two or three times higher rate in cardiovascular disease (CVD) 
compared to non-diabetics (8). Diabetes increases the rate of amputation 10-20 times 
because of infected, non-healing foot ulcers (9).   
Excess body fat and physical inactivity are the strongest risk factors for type 2 
diabetes. Regular physical activity is shown to effectively reduce blood glucose and is an 
important contributor to control weight, and prevent overweight or obesity, all of which 
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are linked with higher diabetes prevalence (10). Therefore, the more prevalent physical 
inactivity worldwide is of increasing concern. Specifically, physical inactivity among 
adolescents is alarmingly high, with 84% of girls and 78% of boys falling under the 
minimum standards of physical activity. Similar with physical inactivity, being overweight 
or obese is also strongly associated with diabetes. According to a global estimate, more 
than one in three adults aged over 18 years was overweight and more than one in 10 was 
obese (2). Higher waist circumference and higher body mass index (BMI) are strongly 
associated with an increase in risk of type 2 diabetes (11). 
 
Molecular Mechanism of Type II Diabetes  
Molecular Mechanism of Insulin Secretion  
The function of -cells depends on their capability to sense blood glucose changes 
in the environment (12). The well-acknowledged pathway of glucose stimulated insulin 
secretion (GSIS) involves two parts: triggering and amplification (13). Elevated blood 
glucose increases glucose influx into the -cell through Glut-2 which quickly equilibrates 
glucose across membrane. Glucose metabolism was increased because of high sensitivity 
(high Km) of glucokinase to glucose, and that leads to elevated ATP/ADP ratio, which 
results in closure of ATP-sensitive K+ (KATP) channels and subsequently depolarizes the 
cell membrane. Voltage-gated Ca2+ channels open in response to the depolarization of the 
plasma membrane. A rise in intracellular Ca2+ is a prerequisite for exocytosis of insulin 
granules from the immediately releasable pool (14).  
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The amplification pathway of insulin release has been suggested to involve a 
number of factors generated from glucose and fatty acid metabolism (14) (15),  some of 
which are described below. Long chain acyl-CoA (LC-CoA) is a major source of energy 
for pancreatic -cells under physiological glucose levels (16). Increased glucose 
metabolism induces a rise in malonyl-CoA, which is known to inhibit carnitine palmitoyl-
transferase I (CPT I) activity and therefore fatty acid oxidation. As a consequence, the LC-
CoA ester level would rise in the cytoplasm providing increased availability to form 
signaling molecules in -cells (15). LC-CoA stimulated fusion of secretory granules to the 
cytoplasmic membrane thereby amplifying secretion (17). It is also observed in -cells that 
increased malonyl-CoA levels were correlated with elevated de novo lipid synthesis and 
diacylglycerol (DAG). DAG is a known activator of protein kinase C (PKC), the activation 
of which is known to stimulate insulin release (18). In addition, -glycerophosphate (-
GP), which is a glucose metabolite derived from glycolysis, also participates in the 
synthesis of DAG. Therefore, malonyl-CoA and -GP are important regulators of 
amplifying pathways of insulin release. Metabolic signals activate phospholipase C (PLC) 
through an elevated cytosolic Ca2+ level and possible other pathways. PLC then hydrolyzes 
phosphatidyl-myo-inositol 4,5-bis-phosphate (PIP2) and produces inositol 1,4,5-P3 (IP3), 
whose main function is to amplify the Ca2+ signal, and DAG, which serves multiple 
purposes as a second messenger to phosphorylate proteins through activation of protein 
kinase C (PKC) (14) (18), and to directly stimulate exocytosis by binding to Munc13-1 
(19).  
Oscillatory Pattern of Ca2+ and Insulin Secretion 
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Oscillations in insulin secretion have been shown to exist in perifused clonal insulin-
secreting-cell lines, dissociated islets and intact islets (20) (21). The importance of this 
oscillatory pattern in insulin release is highlighted by the fact that it is often impaired or 
defective in patients with type 2 diabetes (22). A generally accepted model proposed that 
oscillations in glucose metabolism are implicated in Ca2+ oscillations and drive oscillations 
in insulin release. After glucose enters -cells through the Glut-2 transporter, it is 
phosphorylated by glucokinase, which is known as the glucose sensor since it regulates 
glucose influx by sensing the physiological concentration of glucose (23). In addition to 
phosphorylation by glucokinase, glucose influx is furthered by phosphofructokinase-1 
(PFK-1). PFK-1 is allosterically regulated. It is activated by AMP and fructose 1, 6-
biphosphate and inhibited by ATP. The mechanism of PFK-1 being activated by its product 
provides exquisite sensitivity to the energy state of the cell (24).  The autocatalytic activity 
of PFK-1 results in bursts of ATP production from reactions downstream of glycolysis and 
citric acid cycle, which in turn inhibits PFK-1 activity and causes oscillation of ATP/ADP 
ratio (25). The oscillating ATP/ADP ratio is implicated in closing and reopening of KATP 
channels, which subsequently causes depolarization of the plasma membrane, Ca2+ influx 
(13) and insulin release in an oscillatory pattern (26) (15). But oscillations in insulin release 
can be independent of Ca2+ as demonstrated when islets were perifused with 100 µM 
diazoxide and 30 mM KCl to maintain opening of KATP channels and high intracellular 
Ca2+ concentration (20).   
 
Proinsulin biosynthesis and Insulin Secretion 
  
7 
In addition to insulin secretion, the function of beta-cells also includes production 
and storage of insulin. Normally, insulin stores and a readily available insulin pool for 
secretion are maintained by proinsulin biosynthesis (27). In general, nutrients that stimulate 
insulin secretion also promote proinsulin biosynthesis. Glucose can serve as a signal to 
both stimulate glucose induced insulin secretion (GSIS) and proinsulin biosynthesis. Even 
though many nutrients can regulate insulin secretion and proinsulin biosynthesis 
simultaneously, there must be a divergent point of these two functions since the cell 
apparatus and metabolic pathways involved in these two functions are distinct. Prolonged 
exposure to long-chain fatty acid, especially saturated fatty acid such as palmitate has been 
shown to potentiate GSIS but at the same time inhibit glucose-induced proinsulin 
biosynthesis (28) (29). Palmitate can participate in ceramide synthesis as substrate and 
ceramide has been shown to decrease proinsulin biosynthesis (30) through extracellular 
signal-regulated kinases (ERKs) pathway (31) 
 
Hyperinsulinemia, Insulin Resistance, and Glucolipotoxicity, 
Hyperinsulinemia (HI) refers to an increased plasma insulin level at basal glucose 
concentration. Obesity is shown to be associated with a significant elevation in insulin 
secretion at both fasting and post-prandial conditions even when glucose tolerance is 
normal (32). Insulin resistance is tightly linked to hyperinsulinemia by definition and there 
are different theories in explaining this causal relationship. The elevated insulin level has 
been seen as a compensatory response when an individual is systemically insulin resistant 
(33). Alternatively, it has been proposed that HI due to chronic exposure to excess nutrients 
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may be partly responsible for insulin resistance rather than just the consequence of it (34). 
HI has been shown to induce insulin resistance by increasing lipid accumulation in 
peripheral tissue, and down-regulating insulin receptors, namely in hepatocytes (35). Also, 
moderate disruption in insulin secretion using streptozotocin can slow weight gain in B6 
mice on a high fat diet and partially prevent developing insulin resistance. (35)   
Built on the close association of hyperinsulinemia with obesity and the fact that 
GSIS is triggered by glucose influx and possibly amplified by lipids, fatty acids and its 
derivatives, increasing interest has been shown in investigating the concepts of 
glucotoxicity (chronically elevated glucose) (36), lipotoxicity (37), and both, referred to as 
glucolipotoxicity (GLT) (38) to explain the abnormal insulin secretion in T2D. GLT results 
from the combined, toxic effects of elevated glucose and fatty acid on pancreatic beta-cell 
function and survival (38). GLT has been shown to reduce GSIS and inhibit proinsulin 
biosynthesis (39)(40)(41). In contrast, GLT increases basal insulin secretion from the -
cell and causes basal hyperinsulinemia (42).  
The model in figure 1 includes the causal relationship between insulin resistance 
and hyperinsulinemia. GLT caused by excess nutrients can lead to insulin resistance (IR) 
in peripheral tissues such as muscle. The resulting condition of hyperglycemia causes the  
-cell to compensate by increasing insulin release and leads to hyperinsulinemia (HI) 
(shown by green arrows). The left side of the figure predicts that the effect of GLT to 
induce -cell basal hyper insulin secretion (IH) can promote basal HI which can in turn 
exacerbate insulin resistance (shown by red arrows). 
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Long-chain acyl-CoA synthetase  (ACSL)  
Long-chain Acyl-CoA synthetase (ACSL and ACS are used interchangeably) (43) 
is responsible for the conversion of long-chain fatty acid (LC-FA) and coenzyme A (CoA) 
to LC-CoA (44). LC-CoA can consequently enter pathways of -oxidation, desaturation, 
elongation, lipid synthesis including triglyceride (TG) synthesis, cholesteryl ester (CE) 
synthesis and signaling molecules such as diacylglycerol (DAG) and ceramide (45).   
Figure 1. Model illustrating the contributions of insulin hypersecretion 
(IH) and hyperinsulinemia (HI) in the development of insulin resistance 
(IR) under glucolipotoxic (GLT) environment.  
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Five ACSL isoforms (ACS1-5) were cloned from rats (46)(47)(48). ACSL 
isozymes have specific tissues and organelle distribution. Among them, ACSL5, having a 
molecular mass of 70 kDa, is highly expressed in intestine and also present in liver (46). 
Also, ACSL5 is the only isoform that is located on the mitochondrial outer membrane (46). 
For comparison, ACSL1 is a membrane protein in endoplasmic reticulum (ER) (49) 
whereas ACSL4 is primarily found in mitochondrial associated membrane (MAM) (43). 
These different locations indicate that each ACSL isoenzyme could work independently 
and be responsible for different pathways.  
Triacsin C is a known ACSL inhibitor, can be used to block the conversion of fatty 
acids to LC-CoA. Triacsin C has been used to acutely affect lipid metabolism in INS-1 
cells and the authors found no obvious effects on glycolytic flux or GSIS (51). Use of 
inhibitors of ACSL has also suggested the existence of different acyl-CoA pools inside 
cells, as these inhibitors are capable of inhibiting only part of the acyl-CoA related 
pathways (49).  
All isoforms of ACSL belong to a luciferase superfamily because they contain two 
luciferase-like structures and a linker to connect them. An AMP-binding site and a 
predicted fatty acid binding site locate in the two luciferase-like regions (48). Notably, 
ACSL1, ACSL2, and ACSL5 share more than 60% similar structure and amino acids. 
Despite the high degree of resemblance, the ACSL1 and ACSL5 mRNA expression is 
regulated independently. In liver, ACSL1 mRNA level was elevated after 24 hr fasting (52). 
In the intestine ACSL5 mRNA was unchanged after different diet in mice, but that in liver 
was significantly decreased by fasting (46) and increased by refed after 24 hr fasting (52).  
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The specific role for ACSL5 in cells has yet to be completely established.  ACSL5 
has a broad substrate specificity for saturated (12-18 carbons long) and unsaturated fatty 
acids (16-20 carbon long) (46). ACSL5 mRNA does not change during adipocyte 
differentiation (53). The high level expression of ACSL5 mRNA in intestine epithelial cells 
suggests the role of uptake of dietary fatty acid (46). Its mRNA level was also increased 
with a rise in glucose dose in culture media and in the presence of insulin in primary 
hepatocyte (52). Overexpression of ACSL5 in rat hepatoma is associated with higher acyl-
CoA synthetase activities and increased rate of de novo synthesis of TG and re-acylation 
pathways of synthesizing TG without increasing the metabolism of fatty acids (54). It has 
also been recently reported that ACSL 5 expression ablated mice had increased metabolic 
rates and insulin sensitivity, along with delayed triglyceride absorption leading to 
decreased fat mass (55).  
 
The transcription factor 7 like 2 (TCF7L2) gene and ACSL5 
The gene encoding transcription factor 7 like 2 (TCF7L2) is reported to be one of 
the genes consistently and strongly associated with type 2 diabetes in Genome-wide 
association studies (GWASs) (56) (57). However, genes reported by GWASs are linked to 
a given trait but sometimes not the precise culprit gene. Many studies have been conducted 
to understand the effect of TCF7L2 in the pathogenesis of type 2 diabetes mellitus however 
a clear role for this gene has not been established. Therefore, it is still not clear that TCF7L2 
is actually the culprit gene affecting diabetes. Studies on the role of TCF7L2 have 
concentrated on several tissues including pancreatic islets (58), liver (59), adipose tissue 
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(60) and intestinal cells (61). Among them, studies on intestinal cells may be the most 
plausible since the TCF7L2 gene and -catenin, its binding partner, mediate proglucagon 
gene regulation.  Proglucagon is cleaved into glucagon-like peptide (GLP-1) in the 
intestinal tract (62). GLP-1, produced by enteroendocrine L cells in response to food intake 
(63), is an incretin and accounts for 50-70% of post prandial insulin secretion (64). This 
response initiated by GLP-1 is impaired due to reduced GLP-1 concentration in type 2 
diabetes patients (65). Furthermore, brain GLP-1 mediates glucose and food intake 
homeostasis, possibly through repressed AMPK activity (66). 
The present consensus as a result of fin3 mapping is that the T allele of rs7903146 
within TCF7L2 is the causal variant that is associated with type 2 diabetes (67)(68)(69). 
Following this direction, using genome editing, microarrays and chromatin conformation 
capture it has recently been shown that the ACSL5 gene is located in the same topologically 
associating domain as TCF7L2 (62). ACSL5 mRNA is consistently reduced when 
conducting additional deletion of 66-104 base pairs containing rs7903146. In fact, the 
deletion of this SNP region in a human intestinal related cell line abolished chromatin 
contacts with the ACSL5 promoter and these two regions were conserved in human colon 
tissues (62).  
 
Adipo C putative ACSL5 inhibitor 
After screening compound libraries the Adipogenics Co. discovered a particular 
compound that was effective in reducing FA incorporation into lipid of cultured human 
differentiated preadipocytes. Adipogenics went on to further characterize this inhibitor 
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both in cell culture of differentiated preadipocytes and in mice. The compound referred to 
here as Adipo C, was shown to dose dependently inhibit fluorescent Bodipy FA uptake 
into differentiated preadipocytes and its subsequent incorporation into intracellular lipids. 
The compound inhibited ACSL activity in cell extracts and specifically reduced the level 
of ACSL5 in these cells as shown by western blot of ACSL isoforms. The compound also 
reduced weight gain in mice on a high fat diet.  
In this thesis we have attempted to characterize this putative ACSL5 inhibitor in 
clonal pancreatic ß-cells (INS-1) and to determine its effects on lipid accumulation, 
intracellular Ca2+, insulin content and secretion.   
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METHODS 
INS-1 cell culture  
INS-1 cells (832/13) (31) were cultured in RPMI 1640 containing: 11 mM glucose, 
10% Fetal Bovine Serum (FBS), 50 IU/ml penicillin and 50g/ml streptomycin, 10mM 
Hepes, 1 mM pyruvate, 2 mM L-glutamine and 50 M -mercaptoethanol. In addition, 
glucose was added to RPMI without glucose to achieve 4 mM glucose RPMI 1640 and 
used with the same additives.  Cells were cultured at 37˚ C in humidified atmosphere (5% 
CO2 -95% air). INS-1 cells were used between passages 60-80. 
 
Adipo C compound 
Adipo C is the name we use for the putative ACSL5 inhibitor discovered by the 
Adipogenics Co. Adipo C compound is reconstituted in dimethyl sulfoxide (DMSO) to 10 
mM and 25 mM concentration and stored as aliquots at -20˚ C. The compound is diluted 
1000X in media to achieve 10 µM and 25 µM for culture.  
 
BODIPY fatty acid (BFA) preparation 
 BFA was purchased from Invitrogen (Molecular Probes) as an 11 carbon chain 
length with a terminal Bodipy moiety (C11). 1 mg was dissolved in 20 µL DMSO and 
complexed to 6.7 % bovine serum albumin (BSA) at 50˚ C to a 2 mM concentration of a 
6:1 BFA to BSA molar ratio. DMSO was equal to or less than 0.1% when added to culture. 
 
BFA incorporation and thin layer chromatography (TLC) 
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INS-1 cells cultured in 11mM Glucose RPMI 1640 were preincubated with 2 mM 
glucose media for 2hrs and then in Krebs buffer (containing 110 mM NaCl, 4.6 mM KCl, 
5 mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 0.15 mM Na2HPO4, 0.4 mM KH2PO4, 20 
mM HEPES, 0.05% BSA, pH 7.4) with Adipo C compound or DMSO for 30 mins. Cells 
were changed to test solutions containing 100 µM BFA and incubated 2 hrs at 37˚ C to 
measure BFA incorporation into neutral lipids. Test solutions included Krebs buffer 
containing 1 and 12 mM glucose with or without 10 µM Adipo C compound. At the end 
of 2 hrs methanol was added to wells to fix cells, which were scraped out and transferred 
to a glass tube. Chloroform was added to achieve a 2:1 chloroform:methanol (CM) ratio 
for lipid extraction. Lipids were then dried and stored at -20˚ C prior to lipid separation. 
Dried lipid was solubilized using CM and applied to Silica coated glass TLC plates 
(Whatman), which were oven dried at 100˚ C for 30 mins. Lipids were separated using a 
mobile phase composed of: hexane: diethyl ether: acetic acid (60: 38.5: 1.5). 
Epifluorescence from BFA was detected using 460 nm excitation and >515 nm emission 
wavelengths using a gel imager (GE Healthcare Life Science).  
 
Nile Red 
Nile red (Sigma) was reconstituted in DMSO (1 mg/ml) and added to cells at a 
1:1000 dilution in 2 mM glucose RPMI media to a final concentration of 1 µg/ml. After 15 
mins incubation Nile red was removed and cells were incubated in 2mM glucose RPMI. 
Pictures were taken using a Nikon TE200 microscope with excitation and emission 
wavelengths of 488 and 515 nm and 20X magnification.  
  
16 
  
Insulin Secretion 
INS-1 cells were cultured in 96-well plates (Corning, Corning, NY) to an 
approximate density of 100,000 cells/well and incubated for 72 hrs with or without Adipo 
C (10-25 µM). INS-1 cells were preincubated with RPMI containing 2mM glucose without 
serum for 2 hrs in the culture incubator. After 2 hrs cells were preincubated in 1mM glucose 
Krebs at 37˚ C for 30 mins. Test solutions were then added and incubated in a 37˚ C water 
bath for 2 hrs.  Samples were then collected for insulin assay. For insulin content, cells 
were first detached using trypsin and counted using a hemocytometer, lysed in cold PBS 
containing 0.1% Triton X-100 (Sigma) and 25 mM NaOH and diluted in the same volume 
of 1% BSA Krebs buffer for insulin assay. 
 
Insulin Assay 
Insulin was measured in 1536 well plates using the HTRF insulin assay (Cis-Bio, 
Bedford, MA) using a Tecan M1000 Pro fluorescence plate reader. 
 
Ca2+ Measurement 
Intracellular Ca2+ in INS-1 cells was measured using fura-2 AM (Invitrogen, 
Carlsbad, CA). INS-1 cells were cultured in glass bottom 35 mm dishes (MAtTek, Ashland, 
MA). The glass bottom dishes were coated with poly-D-lysine to allow better cell 
attachment. Cells were treated with Adipo C as described above for insulin secretion. INS-
1 cells were preincubated with 2mM glucose RPMI for 1 hr prior to fura loading. 2 µM 
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Fura 2 AM was loaded into cells in 2mM glucose RPMI with 0.1% pluronic acid for 30 
mins. Fura 2 AM was removed and cells incubated for an additional 15 min for cleavage 
of the dye trapping free fura inside the cells. Imaging was performed on an Olypmus DSU 
spinning disk confocal microscope at 37˚ C and 20X magnification. Fluorescence images 
were captured every 15 sec using wavelengths of 340 and 380 nm dual excitation and 510 
nm emission. Data were analyzed using Nikon Sensing software.  
 
Formation of INS-1 cell spheres and measurement of insulin oscillations 
15 million INS-1 cells were plated in non-cell culture treated 60 mm dishes in 
RPMI. After 24 hrs cell colonies were divide into separate dishes with or without 25 µM 
Adipo C to continue forming spheres 3 days before the experiment. On day of the 
experiment separated spheres were collected and pre-inbubated in 2 mM glucose RPMI for 
2 hrs. Spheres were then loaded onto columns of cytodex beads (Sigma) maintained in a 
37˚ C  chamber and perifused with 1 mM glucose Krebs buffer solution for 30 min prior to 
collecting fractions at 15 sec intervals for 72 mins. Cells were perifused with 1 mM glucose 
(20 mins), 3 mM glucose (20mins), 12mM glucose (20mins) and 12 mM glucose + 30 mM 
KCl (12 mins). Insulin secretion was measured and analyzed as described above.  
 
Statistical Analysis 
The data are calculated as the mean of independent experiments and error bars are 
calculated as standard error (SE). Statistical significance was calculated by two-tailed 
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Student’s t test or paired t-test where indicated. A p value of < 0.05 indicates significant 
change as indicated in figure legends. 
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RESULTS 
 
Adipo C inhibits BFA incorporation into lipid 
C11 BFA was used to track LC-CoA incorporation into lipids including triglyceride 
(TG), diglyceride (DG), and monoglyceride (MG). A representative TLC separation of 
lipid extracts from INS-1 cells incubated in 1 and 12 mM glucose with C11 BFA and with 
or without acute exposure to 10 µM Adipo C for 2 hrs is shown in Figure 2. Lipid extracts 
from cells incubated in 12 mM glucose without Adipo C exposure showed increased 
incorporation of BFA into all three types of lipids (MG, DG, TG) compared to that from 
cells incubated in 1 mM glucose (compare lane 2 to 1). Adipo C treated cells showed less 
incorporation of BFA when glucose was raised from 1 to 12 mM (compare lane 4 to 3). In 
addition it appeared that Adipo C reduced basal incorporation of BFA into DG (compare 
lane 3 to 1). When C16 BFA was used instead of C11 BFA no difference in  MG and TG 
incorporation was observed between control and Adipo C exposed group (data not shown).  
Adipo C exposure decreased some of the DG lipid levels stimulated by high glucose. 
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Figure 2. Acute exposure to Adipo C reduces glucose induced lipid 
incorporation. Thin layer chromatogram (TLC) of lipid extracts with BODIPY 
fatty acid from INS-1 cells incubated in 1 or 12 mM glucose in the presence or 
absence 10 µM Adipo for 2 hrs. Triglyceride (TG), diglyceride (DG), and 
monoglyceride (MG) are indicated by arrows. Control was 0 µM Adipo C with 
0.1 % DMSO. 
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Adipo C reduces intracellular lipid droplets 
Nile red was used to stain intracellular TG lipid droplets in INS-1 cells cultured in 4 mM 
glucose and cells switched from 4 mM to 11 mM glucose for 72 hr with and without 10 
µM Adipo C (Figure 3). Cells chronically cultured in 4 mM glucose (panel A) exhibited 
less lipid droplets (represented by bright dots) compared to cells switched to 11 mM 
glucose for 72 hrs (panel C), consistent with previous data from our lab (Erion) (42). Cells 
chronically cultured in 4 mM glucose media with 10 M Adipo C exhibited no apparent 
difference in lipid droplet level compared to the control (compare panel B to panel A). 
Cells switched to 11 mM glucose media with 10 M Adipo C showed reduced level of 
lipid droplets compared to 11 mM glucose control condition (compare panel D to panel C). 
This result seems to be due to a reduction in both the number and size of lipid droplets.  
  
22 
 
 
 
 
Adipo C exposure increases doubling time of INS-1 cells in culture  
 INS-1 cells were cultured staring at a know cell density in 96-well plates and the 
number of cells per well were counted after 4-6 days. Doubling time of INS-1 cells 
chronically cultured in 11mM glucose RPMI (>2weeks) with or without exposure to 
Figure 3. Chronic exposure to adipo C reduces lipid droplets in INS-1 
cells. INS-1 cells were cultured in 4G with (B) and without (A) Adipo C, or in 
11G with (D) and without (C) Adipo C. for 72 hrs.  Lipid droplet were assessed 
with the dye Nile red and representative pictures were taken at 20 
magnification. 
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increasing concentration of Adipo C compound for 72 hrs were calculated. Cells 
chronically cultured in 11 mM glucose (blue bar) replicated at a rate of 34 hrs/ doubling 
time. Adipo C exposure resulted in a significant decrease in the rate of growth of INS-1 
cells increasing the doubling time of cells cultured in 11 mM glucose with 10 µM (green 
bar)  and 25 µM Adipo C (red bar)  compared to the 11 mM glucose control. The doubling 
time increased from 34 hrs to 40 hrs and 47 hrs for 10 µM and 25 µM Adipo C treated 
cells, respectively. No significant difference in doubling time was observed between 11G 
cells cultured with 10 µM and 25 µM Adipo C.  
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Figure 4. Chronic exposure to Adipo C increases doubling time for INS-
1 cells.  INS-1 cells were cultured in 0 (blue bar), 10 (green bar) or 25 (red 
bar) µM Adipo C for 72 hrs. Doubling time was calculated. Doubling time 
was measured from 5 independent experiments. Error bars represent  SE. 
(*, p<0.01 compared to control group; #, p<0.05 compared to control group). 
Control was 0 µM Adipo C with 0.1 % DMSO. 
  
24 
The effect of Adipo C on glucose induced insulin release 
To characterize the effect of Adipo C on glucose induced insulin release, insulin 
secretion was measured from INS-1 cells cultured in 11 mM glucose RPMI media with 
and without 72 hrs exposure to increasing concentrations of Adipo C compound (Figure 
5). Cells cultured without Adipo C (blue bars) exhibited a dose-dependent increase in GSIS 
from 1 to 12 mM glucose. Both 3 and 12 mM glucose significantly increased insulin 
secretion compared to basal (1 mM) glucose. The increase at 3 mM glucose was consistent 
with Erion et al. demonstrating that INS-1 cells cultured in 11 mM glucose exhibit a left-
shift in the glucose dose-response for insulin secretion (42). When cells were exposed to 
10 (green bars) or 25 (red bars) µM Adipo C, basal insulin secretion was increased although 
this was not statistically significant. In contrast to the control condition, Adipo C treated 
cells showed no increase in insulin secretion when glucose was increased from 1 to 3 mM 
glucose. This suggests that Adipo C can reverse the left-shift in insulin secretion from cells 
cultured in 11 mM glucose. Adipo C increased 12 mM GSIS and this was significant at 25 
µM concentration (red bars).  
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The changes in basal insulin secretion in cells treated with 10 µM and 25 µM Adipo 
C prompted us to study whether this increase was due to an increase in the level of 
intracellular Ca2+. Insulin secretion was measured from INS-1 cells cultured in 11 mM 
glucose RPMI media with and without 72 hr exposure to increasing concentrations of 
Adipo C compound (Figure 6). INS-1 cells cultured without Adipo C compound had a 
significant increase in insulin secretion at 3 mM glucose condition compared to 1 mM 
glucose (Figure 6 blue bars). This increase of insulin secretion is characterized as an 
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Figure 5. Chronic exposure to Adipo C increases GSIS from INS-1 cells.  
INS-1 cells were cultured in 0 (blue bars), 10 (green bars) or 25 (red bars) µM 
Adipo C for 72 hrs. Insulin secretion was measured at 1, 3 and 12 mM glucose 
for 2 hours. Insulin secretion was measured from 5 independent experiments. 
Error bars represent  SE. (*, p<0.05 compared to control group at 1 mM 
glucose; #, p<0.05 compared to control at 12 mM glucose). Control was 0 µM 
Adipo C with 0.1 % DMSO. 
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important sign of glucolipotoxicity according to Erion et al (42). The increase was 
alleviated in INS-1 cells cultured in 11 mM glucose RPMI with 10 µM (Figure 6 green 
bars) and 25 µM (Figure 6 red bars) Adipo C compound in a dose dependent manner. INS-
1 cells cultured without Adipo C compound had a significant decrease in insulin secretion 
in 3mM glucose with diazoxide (DZ) (K+ ATP channel activator) compare to that of 3 mM 
glucose. Diazoxide showed less or no inhibition in 10 µM (green bars) and 25 µM (red 
bars) Adipo C concentration, which indicates that the insulin secretion of INS-1 cells 
cultured with Adipo C at 1 and 3 mM glucose is not due to increased Ca2+ influx; And the 
increased insulin secretion from 1 to 3 mM glucose observed in control cells is due to 
increased Ca2+ influx.  
Similar trend was seen in INS-1 cells cultured in 4 mM glucose, which is considered 
a physiological concentration and has better resemblance to islets (39). In 4G cells, insulin 
secretion at dose-responsive GSIS curve did not show difference between cells cultured 
with (Figure 7, panel A-green shadowed) or without Adipo C (Figure 7, panel A blue 
shadowed). In addition, when glucose increased from 1 to 3 mM, insulin secretion did not 
increase in both 4G cells cultured with (Figure 7, panel C-green shadowed) or without 
Adipo C (Figure 7, panel C-blue shadowed). After switch 4G cells to 11G RPMI media for 
72 hrs without Adipo C , GSIS was blunted (Figure 7- panel B blue bars) whereas cells 
cultured with Adipo C (Figure 7- panel B green bars) showed restored GSIS. In contrast 
with chronic 4G cells, 4G switched to 11G without Adipo C (Figure 7- panel B blue bars) 
has an increase in secretion when glucose level was elevated from 1 to 3 mM. When 4G 
cells were exposed to with 10 µM Adipo C for 72 hrs, the increase at 3 mM glucose 
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compare to 1 mM glucose was blunted. Taken together, data on 4G cells transferred to 11 
mM glucose RPMI for 72 hrs with or without Adipoc is in great consistency with Erion et 
al. (42) and chronic 11G cells (figure 5, 6), which showed that 11G exhibited a left-shift in 
the glucose dose-response for insulin secretion and this secretion is, at least partially, 
rescued by Adipo C compound. 
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Figure 6. Chronic exposure to adipo C alleviate Increased basal insulin 
secretion in a dose dependent manner. INS-1 cells were cultured in 0 (blue 
bars), 10 (green bars) or 25 (red bars) µM Adipo C for 72 hrs. Insulin secretion 
was measured at 1, 3 mM glucose and 3mM glucose with Diazoxide (DZ) for 
2 hours. Insulin secretion was measured from 5 independent experiments. 
Error bars represent  SE. (*, p<0.05 compare to control group at 1 mM 
glucose; #, p<0.05 compare to control at 12 mM glucose). Control was 0 µM 
Adipo C with 0.1 % DMSO. 
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Figure 7 Chronic exposure to Adipo C rescues reduced GSIS and 
alleviates increased basal insulin secretion in 11G cells. INS-1 cells were 
cultured in 4 mM glucose RPMI and then transferred to 0 (blue bars), 10 
(green bars) µM Adipo C for 72 hrs in 4 mM or 11 mM RPMI. Insulin secretion 
was measured at 1, 3, 12 mM glucose and 3 mM glucose with Diazoxide for 
2 hours. Insulin secretion was measured from 1 independent experiment. 
Error bars represent  SE. Control was 0 µM Adipo C with 0.1 % DMSO. 
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Adipo C increases insulin Content 
To determine whether the increase of insulin release at high glucose is due to 
increased insulin content, we measured total insulin from INS-1 cells cultured in 11 mM 
glucose RPMI media with and without 72 hr exposure to increasing concentrations of 
Adipo C compound (Figure 8). INS-1 cells cultured with 10 µM Adipo C (green bar) had 
a 25% increase in insulin content compared to the control group (blue bar). Insulin Content 
in INS-1 cells cultured with 25 µM Adipo C (red bar) increased 84% compared to the 
control group. 
Insulin secretion was then calculated as a percentage of insulin content from INS-
1 cells (Figure 9). GSIS as a percentage of the total insulin content was similar among the 
three conditions (control, 10µM Adipo C, 25 µM Adipo C). A similar trend was observed 
across insulin secretion at 1 mM glucose and 3 mM glucose. This suggests the increased 
insulin secretion at 3 mM and 12 mM glucose in Adipo C treated groups observed in Figure 
6 largely results from increased insulin content. 
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Figure 8. Chronic exposure to Adipo C increases insulin content in INS-
1 cells.  INS-1 cells were cultured in 0 (blue bars), 10 (green bars) or 25 (red 
bars) µM Adipo C for 72 hrs. Insulin content was calculated as a percent of 
the control without Adipo C, which was set at 100 %. Insulin content of INS-
1 cells without Adipo C was used as 100 %. Insulin content was measured 
from 5 independent experiments. Error bars represent  SE. (*, p<0.05 
compare to control group at 1 mM glucose; #, p<0.05 compare to control at 
12 mM glucose). Control was 0 µM Adipo C with 0.1 % DMSO. 
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Figure 9. Chronic exposure to Adipo C increases GSIS through 
increased insulin content. INS-1 cells were cultured in 0 (blue bars), 10 
(green bars) or 25 (red bars) µM Adipo C for 72 hrs. Insulin secretion was 
measured at 1, 3 and 12mM glucose (Figure 6) and then calculated as a 
percent of total insulin content. Insulin secretion and insulin content was 
measured from 5 independent experiments. Error bars represent  SE. 
Control was 0 µM Adipo C with 0.1 % DMSO. 
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Intracellular Ca 2+ measurement  
Figure 7 shows that cells switched from 4 to 11 mM glucose exhibited a left-shift 
in glucose-induced secretion, which was abolished by diazoxide (compare blue bars in 
panel C and D). Since it was observed that Adipo C prevented this left-shift in secretion 
we were interested in examining intracellular Ca2+ activity in response to the same glucose 
concentrations (Figure 10). The extracellular glucose was raised from 1 mM glucose (0-15 
min) to 3 mM glucose (15-30 min) and then to 12 mM glucose (30 min-end of trace) in 
fura 2 loaded cells. Cells cultured in 4 mM glucose (Figure 10, panel A) and cells switched 
from 4 to 11 mM glucose in the absence (Figure 10, panel B) or presence of 10 µM (Figure 
10, panel C) and 25 µM (Figure 10, panel D) Adipo C for 72 hrs were imaged.   
Cells in 11 mM glucose in the absence of Adipo C (Figure 10, panel B) exhibited 
apparent increase in Ca2+ activity when glucose level was raised from 1 to 3 mM but failed 
to further increase the level of Ca2+ when it was switched to 12 mM glucose. Whereas cells 
cultured in 4 mM glucose barely responded to the same low glucose increase (1 to 3 mM) 
but exhibited high level of Ca2+ activity in response to stimulatory glucose level (12 mM 
glucose) (Figure 10, compare panel A to B). Cells grown in 11G and 10 µM Adipo C 
(Figure 10, panel C) had no obvious increase in Ca2+ activity level when glucose was 
increased from 1 to 3 mM resembling 4 mM glucose cells, but showed a lag in increasing 
Ca2+ activity at 12 mM glucose level compare to 4G cells (Figure 10, compare panel C to 
A). 11 mM glucose cells cultured with 25 µM Adipo C (Figure 10, panel D) presented a 
better resemblance to the 4 mM glucose control group both in lack of basal Ca2+ activity 
(from 1 to 3 mM glucose) and an active stimulatory response at 12 mM glucose that 
  
33 
resulted in a more rapid rise in intracellular Ca2+ (Figure 10, compare panel D to A). 
Similarly, 11G cells culture in the presence of 25 µM Adipo C (Figure 10, panel D) 
exhibited damped oscillation at 1 and 3 mM glucose but a quicker and more active response 
when stimulatory glucose was added compare to 11G cultured in the absence of Adipo C 
(Figure 10, compare panel D to B).  
 
Figure 10. Chronic exposure to Adipo C changes the oscillating pattern 
of intercellular Ca2+. 4G cells were transited to 4 mM glucose media (panel 
A), 11 mM glucose in the absence (panel B) or presence of 10 µM (panel C), 
25 µM (panel D) Adipo C for 72 hrs. Intercellular Ca2+level was measured as a 
ratio of fluorescence at 340/380 dual excitation. Measurement was taken 
every 15s for at least 45 mins, consisted of 31 cells per trace, including 1 mM 
glucose (0-15 mins), 3 mM glucose (15-30 mins), 12 mM glucose (30mins -
end of trace). Control was 0 µM Adipo C with 0.1 % DMSO. 
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Insulin Oscillation 
In order to determine whether Adipo C affected the oscillatory pattern of insulin 
secretion we performed column perifusion experiments. INS-1 cell spheres were incubated 
with (red line) or without (blue line) 25 µM Adipo C for 72 hrs, loaded onto columns of 
cytodex beads and perifused with varying glucose concentrations while collecting 15 sec 
fractions for insulin analysis. Spheres were perifused with 1 mM glucose (1-20 mins), 3 
mM glucose (20-40 mins), 12 mM glucose (40-60 mins) and 12 mM glucose with 30 mM 
KCl (60-72 mins). Both Control and Adipo C treated cells exhibited a regular oscillatory 
pattern.  Oscillations from control cells were of higher amplitude throughout the time 
course of secretion. The pattern of oscillations was altered in the control cells after 
increasing glucose from 1 to 3 mM.  This could be due a left-shifted glucose response in 
these cells. This altered pattern was less obvious in cells treated with Adipo C. Cells 
cultured with Adipo C (red line) for 72 hrs exhibited a robust increase in insulin secretion 
to 0.4 ng/ml with stimulatory glucose (12 mM) glucose and continued to oscillate at that 
level. The increase in secretion observed in control cells (blue line) was very much blunted. 
The difference in the oscillatory amplitude was marked when cells were depolarized with 
KCl, with control cells exhibiting larger amplitude oscillations compared to cells treated 
with Adipo C.  Taken together, cells cultured with Adipo C exhibited a higher insulin 
secretion level compare to cells cultured in control condition, with similar period but 
reduced amplitude oscillations.  
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Figure 11 Chronic exposure to Adipo C does not change oscillatory pattern of 
insulin secretion but decrease the amplitude. INS-1 cells formed colonies were 
cultured in 11 mM glucose media with (red line) or without (blue line) 25 µM Adipo 
C for 72 hrs. Insulin secretion was measured over a time lapse of 72 mins with 
glucose increasing from 1 mM (20mins), 3mM (20mins) to 12 mM glucose 
(20mins) and 12 mM glucose with 2 mM KCL (12 mins). Control was 0 µM Adipo 
C with 0.1 % DMSO. Make calcultions of the level and range. 
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DISCUSSION 
 In this thesis we have explored the effects of a compound that is thought to inhibit 
ACSL5 on lipid accumulation and insulin secretion from clonal pancreatic ß-cells. We have 
named this putative inhibitor compound Adipo C.  Adipo C exhibited the ability to acutely 
inhibit fatty acid incorporation into INS-1 cells while reducing intracellular lipid stores in 
these cells after 72 hrs incubation. Reducing lipid in INS-1 cells using this inhibitor 
mimicked many of the same changes that we have observed when intracellular lipid was 
reduced by lowering the glucose concentration in culture (42). These changes include a 
reduced growth rate, increased insulin content, a more rapid and robust intracellular Ca2+ 
response to high glucose, a right-shift in the glucose dependent insulin secretion and 
increased GSIS. Some changes that were not seen before include decreased amplitude 
oscillations in both intracellular Ca2+ and insulin secretion.  
The ability of Adipo C to inhibit ACSL activity has been suggested by the 
observation that BFA incorporation into neutral lipids of INS-1 cells was dramatically 
reduced in Adipo C treated cells compared to control. The decreased incorporation was 
observed for MG, DG and TG and all may play a role in basal insulin hypersecretion and/or 
GSIS. DG has been shown to stimulate PKC isozymes that influence exocytosis (70) and 
bind Munc13-1 to stimulate insulin exocytosis (19). TG may play a role by supplying FA 
as a product of lipolysis, a process that has been shown to be critical for maintenance of 
normal GSIS (71). 
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The required specific assay to determine that inhibition of ACS activity is the cause 
of the reduced incorporation has not been performed at the time of writing this thesis. We 
still cannot rule out inhibition of acyl transferase activity, which could yield a similar 
outcome. 
The acute effect of Adipo C to reduce lipid incorporation evidenced by TLC, can 
lead to cellular lipid depletion illustrated by the long-term loss of intracellular lipid 
droplets. Lipid droplets are a marker of excess cellular lipid and an indicator of potential 
glucolipotoxicity (42). The ability of Adipo C to reduce the lipid droplets gives it potential 
to protect cells from the glucolipotoxic effect.  
While short-term exposure of FA to islets or -cells potentiates GSIS, chronically 
increased lipid level in INS-1 cells causes a left shift in the glucose dose response of 
secretion characterized by elevated basal insulin secretion and blunted GSIS (42). Our 
results showed in cells chronically cultured in 11 mM glucose or switched from 4 to 11 
mM glucose for 72 hr (exploratory data), insulin secretion was increased when glucose was 
raised from 1 to 3 mM. This represents a left shift in secretion when compared to the lack 
of response in cells cultured in 4 mM glucose. Adipo C prevented this left shift in secretion 
and increased GSIS in cells cultured in high glucose. Taken together, Adipo C compound 
showed the ability to reverse or alleviate the effects of GLT and prevent basal insulin 
hypersecretion that may contribute to hyperinsulinemia and the progression of insulin 
resistance.  
Reduced lipid droplet level clearly affected INS-1 cells in multiple ways. The 
growth rate of INS-1 cells is slowed down and both GSIS and insulin content increased. 
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Notably, the altered insulin content is of great importance when interpreting insulin 
secretion and functional capacity of -cells under GLT as highlighted by Erion et al (42).  
Increased insulin secretion from Adipo C treated cells came to the same level as controls 
after normalizing secretion to insulin content. This suggested to us that the effect of Adipo 
C on insulin secretion may be due to increased insulin content. It has been shown that some 
lipid moieties such as ceramide induced by palmitate inhibit insulin transcription thereby 
reducing insulin biosynthesis (31)(30). Therefore, the increased insulin content in cells 
exposed to Adipo C is potentially associated to reduced fatty acid incorporation into lipids. 
Further studies on the extent of inhibition on ceramide synthesis caused by Adipo C are 
needed to verify this hypothesis.  
It has been previously shown that cells cultured in low glucose respond with a rapid 
and robust intracellular Ca2+ response compared to cells exposed to 11 mM glucose. The 
increased Ca2+ influx in cells cultured at 4 mM glucose correlates well with the increased 
secretion from these same cells. Our Ca2+ traces showed that cells cultured in 4 mM glucose 
have minimal Ca2+ activity at 1and 3 mM glucose and rapidly and robustly increased at 12 
mM glucose consistent with the glucose induced secretion (Fig. 6 panel A blue bar). In 
comparison, cells cultured in 11 mM glucose media alone exhibited the significant increase 
in secretion from 1 to 3 mM glucose, whereas when glucose was raised to 12 mM glucose 
they exhibited attenuated response to Ca2+ and reduced GSIS, which is also consistent with 
its secretion (Fig. 6 panel C blue bar). Comparison of cells cultured in 4 mM glucose and 
11 mM glucose illustrates the effect of glucolipotoxicity on -cells. Our results showed 
striking resemblance between cells cultured in 11 mM glucose with 25 µM Adipo C 
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compound and cells cultured in 4 mM glucose. This serves as strong support for the ability 
of Adipo C compound to protect -cells from basal hyper insulin secretion that may 
participate in the progression of insulin resistance.  
There are possible pitfalls of average Ca2+ activity measurement: 1) instead of 
looking at individual cells, the average is used to represent the level of Ca2+ activity in 31 
separate cells; 2) oscillations would be artificially reduced or diminished during the 
calculations; and 3) the average Ca2+ could mask oscillations due to lack of synchrony 
among cells. 
The oscillations in insulin release are of great importance as the oscillatory pattern 
is impaired in T2D patients (22). The kinetics of insulin secretion revealed similar period 
but altered pattern of oscillation between cells cultured with or without Adipo C. The 
frequency of insulin oscillations seems unaffected, indicating glucose metabolism coupled 
to secretion is intact (20). The amplitude at which they oscillate was seemingly reduced by 
exposure to Adipo C. This may be the result of lack of synchrony between spheres in 
columns, which could mask actual oscillation.  
So far the data we have collected demonstrated that the putative inhibition effect of 
ACSL5 may increase GSIS and reverse the left shift of insulin secretion caused by chronic 
exposure to excess nutrients (42). Other studies have shown using triacsin C, a long-chain 
acyl-CoA synthetase inhibitor, that reducing LC-CoA does not inhibit insulin secretion 
despite changes in fatty acid oxidation and  palmitate incorporation into lipids (51).   The 
discrepancy between their data and our data can be explained by the difference in 
specificity of these two inhibitors. Triacisin C is capable of inhibiting ACSL1 and ACSL4 
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but not ACSL5 (73), but Adipo C is considered as a putative specific ACSL5 inhibitor. 
Different ACSLs vary in their functions and locations inside the cells and it is unlikely that 
inhibiting different ACSLs will produce the same result.  
 Adipo C compound showed protective effect of decreasing intrinsic lipid 
accumulation, preserving insulin content and reversing left shift of glucose induced insulin 
secretion from clonal pancreatic −cells grown in glucolipotoxic environment and no 
adverse effect on clonal pancreatic −cells grown in physiological environment. The 
desirable effect of Adipo C on  −cells warrants further research on Adipo C compound to 
explore its potential as a possible therapeutic agent for T2D patients 
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